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Stem Cell Research
Summary
Embryonic stem cells have the ability to develop into virtually any cell in the
body, and may have the potential to treat medical conditions such as diabetes and
Parkinson’s disease.  In August 2001, President Bush announced that for the first
time federal funds would be used to support research on human embryonic stem
cells, but funding would be limited to “existing stem cell lines.”  The National
Institutes of Health (NIH) has established the Human Embryonic Stem Cell Registry
which lists stem cell lines that are eligible for use in federally funded research.
Although 78 cell lines are listed, 21 embryonic stem cell lines are currently available.
Scientists are concerned about the quality, longevity, and availability of the eligible
stem cell lines.  For a variety of reasons, many believe research advancement requires
new embryonic stem cell lines, and  for certain applications, stem cells derived from
cloned embryos may offer the best hope for progress in understanding and treating
disease.  A significant cohort of pro-life advocates support stem cell research; those
opposed are concerned that the isolation of stem cells requires the destruction of
embryos.  Letters from Congress, one signed by 206 Members of the House and a
second signed by 58 Senators, have been sent urging President Bush to expand the
current federal policy concerning embryonic stem cell research.
Some have argued that stem cell research be limited to adult stem cells obtained
from tissues such as bone marrow.  They argue that adult stem cells should be
pursued instead of embryonic stem cells because they believe the derivation of stem
cells from either embryos or aborted fetuses is ethically unacceptable.  Other
scientists believe adult stem cells should not be the sole target of research because
of important scientific and technical limitations.  Groups make ethical distinctions
in the debate on how to proceed with stem cell research based upon embryo
protection, relief of suffering, viability, the purpose and timing of embryo creation
and destruction, donor consent, scientific alternatives, federal funding, and cloning.
On February 27, 2003, the House passed H.R. 534 (Dave Weldon), which would
ban the process of human cloning and the importation of any product derived from
an embryo created via cloning.  Cloning could not be used for reproductive purposes
or for research on therapeutic purposes, which has implications for stem cell
research. The House defeated a substitute amendment, H.Amdt. 5, that would have
banned only human reproductive cloning; the ban would have sunset after 10 years.
H.R. 801 (Greenwood) is similar to H.Amdt 5.  S. 245 (Brownback) would ban
reproductive cloning and research on therapeutic cloning; S. 303 (Hatch) would ban
only reproductive cloning.  Supporters of H.R. 534 argue that a partial ban on human
cloning, such as S. 303 and H.R. 801, would be impossible to enforce.  Critics argue
that H.R. 534 would curtail medical research and prevent Americans from receiving
life-saving treatments created overseas.  President Bush has stated his support for the
Weldon bill, but 40 Nobel Laureates, who are in favor of nuclear transplantation
technology for research and therapeutic purposes, are strongly opposed to the
legislation.  H.R. 3960 (Millender-McDonald) and H.R. 4682 (Castle) would fund
research on embryonic stem cell lines derived after the August 9, 2001, policy
established by the Bush Administration.  This report will be updated as needed.
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1 The IVF embryos were originally created for the treatment of infertility.  Excess embryos
are often frozen in liquid nitrogen for future use.  A couple may elect to discard their excess
embryos, donate the embryos for research, or allow another couple to adopt an embryo.
2 Scientists and physicians use the term embryo for the first eight weeks after fertilization,
and fetus for the ninth week through birth.  In contrast, the Department of Health and
Human Services (HHS) regulations define fetus as “the product of conception from the time
of implantation.”  (45 CFR 46.203)
3 A somatic cell is a body cell.  In contrast, a germ cell is an egg or sperm cell.
Stem Cell Research
Overview of Basic Research and Potential Applications
Most cells within an animal or human being are committed to fulfilling a single
function within the body.  In contrast, stem cells are a unique and important set of
cells that are not specialized.  Stem cells retain the ability to become many or all of
the different cell types in the body and thereby play a critical role in repairing organs
and body tissues throughout life.  Although the term stem cells is often used in
reference to these repair cells within an adult organism, a more fundamental variety
of stem cells is found in the early stage embryo.  Embryonic stem cells may have a
greater ability to become different types of body cells than adult stem cells.
  
Stem Cells from Embryos or Fetal Tissue.  Embryonic stem cells were
first isolated from mouse embryos in 1981.  Animal embryos were the only source
for research on embryonic stem cells until November 1998, when two groups of U.S.
scientists announced the successful isolation of human embryonic stem cells.  One
group, at the University of Wisconsin, derived stem cells from one-week-old
embryos  produced via in vitro fertilization (IVF).1  The work is controversial, in the
opinion of some individuals, because the stem cells are located within the embryo
and the process of removing them destroys the embryo.  The second group, at Johns
Hopkins University, derived cells with very similar properties from five- to nine-
week-old embryos or fetuses obtained through elective abortion.2  Both groups
reported the human embryos or fetuses were donated for research following a process
of informed consent.  The cells were then manipulated in the laboratory to create
embryonic stem cell lines that may continue to divide for many months to years.
Another potential source of embryonic stem cells is somatic cell nuclear transfer
(SCNT), also referred to as cloning.3  In SCNT the nucleus of an egg is removed and
replaced by the nucleus from a mature body cell, such as a skin cell.  The cell created
via SCNT is allowed to develop for a week and then the stem cells are removed.  In
1996, scientists in Scotland used the SCNT procedure to produce Dolly the sheep,
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4 Dolly  was euthanized in Feb. 2003 after developing a lung infection.  Some claim  her
death at six years was related to being a clone, but her ailment may also have occurred
because she was raised indoors (for security reasons) rather than as a pastured sheep, which
often live to 12 years of age.  G. Kolata, “First Mammal Clone Dies,” New York Times, Feb.
15, 2003, p. A4.
5 For further information, see CRS Report RL31358, Human Cloning, by Judith A. Johnson.
the first mammalian clone.4  In February 2004, Korean scientists announced that they
had created  human embryos via the SCNT process and had succeeded in isolating
human stem cells from a cloned embryo.  This development and the unsubstantiated
announcement by Clonaid in December 2002 of the birth of a cloned child have
contributed to the controversy over research on human embryos.5
Stem Cells from Adult Tissue or Umbilical Cord Blood.  Stem cells
obtained from adult organisms are also the focus of research.  There have been a
number of recent publications on adult stem cells from a variety of different sources,
such as bone marrow and the umbilical cord following birth.  In addition, a number
of private companies (such as MorphoGen, NeuralStem, Osiris Therapeutics,
StemSource, ViaCell) are working on therapeutic uses of adult stem cells. 
Some advocate that adult instead of embryonic stem cell research should be
pursued because they believe the derivation of stem cells from either  IVF embryos
or aborted fetuses is ethically unacceptable.  Others believe that adult stem cells
should not be the sole target of research because of important scientific and technical
limitations.  Adult stem cells may not be as long lived or capable of as many cell
divisions as embryonic stem cells.  Also, adult stem cells may not be as versatile in
developing into various types of tissue as embryonic stem cells, and the location and
rarity of the cells in the body might rule out safe and easy access.  For these reasons,
many scientists argue that both adult and embryonic stem cells should be the subject
of research, allowing for a comparison of their various capabilities.
Possible Sources of Stem Cells
 — embryos created via IVF (for infertility treatment or for research purposes)
 — embryos or fetuses obtained through elective abortion
 — embryos created via SCNT (somatic cell nuclear transfer, or cloning)
 — adult tissues (bone marrow, umbilical cord blood)
Potential Applications of Stem Cell Research.  Stem cells provide the
opportunity to study the growth and differentiation of individual cells into tissues.
Understanding these processes could provide insights into the causes of birth defects,
genetic abnormalities, and other disease states.  If normal development were better
understood, it might be possible to prevent or correct some of these conditions.  Stem
cells could be used to produce large amounts of one cell type to test new drugs for
effectiveness and chemicals for toxicity.  Stem cells might be transplanted into the
body to treat disease (diabetes, Parkinson’s disease) or injury (e.g., spinal cord).  The
damaging side effects of medical treatments might be repaired with stem cell
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6 However, federal funds have been provided for research on both human and animal adult
stem cells and animal embryonic stem cells.
7 The rider language has not changed significantly from year to year.  The original rider can
be found in Section 128 of P.L. 104-99; it affected NIH funding for FY1996 contained in
P.L. 104-91.  For subsequent fiscal years, the rider is found in Title V, General Provisions,
(continued...)
treatment.  For example, cancer chemotherapy destroys immune cells in patients,
decreasing their ability to fight off a broad range of diseases; correcting this adverse
effect would be a major advance.
Before stem cells can be applied to human medical problems, substantial
advances in basic cell biology and clinical technique are required.  In addition, very
challenging regulatory decisions will be required on the individually created tissue-
based therapies resulting from stem cell research.  Such decisions would likely be
made by the Center for Biologics Evaluation and Research (CBER) of the Food and
Drug Administration (FDA).  The potential benefits mentioned above would be likely
only after many more years of research.  Technical hurdles include developing the
ability to control the differentiation of stem cells into a desired cell type (like a heart
or nerve cell) and to ensure that uncontrolled development, such as a cancerous
tumor, does not occur.  If stem cells are to be used for transplantation, the problem
of immune rejection must also be overcome.  Some scientists think that the creation
of many more embryonic stem cell lines will eventually account for all the various
immunological types needed for use in tissue transplantation therapy.  Others
envision the eventual development of a “universal donor” type of stem cell tissue,
analogous to a universal blood donor.
However, if the SCNT technique (cloning) was employed using a cell nucleus
from the patient, stem cells created via this method would be genetically identical to
the patient, would presumably be recognized by the patient’s immune system, and
thus would avoid any tissue rejection problems that could occur in other stem cell
therapeutic approaches.  Because of this, many scientists believe that the SCNT
technique may provide the best hope of eventually treating patients using stem cells
for tissue transplantation.
Current Federal Regulatory Landscape
The Dickey Amendment and Clinton Administration Stem Cell
Policy.  Prior to an August 2001 Bush Administration decision (see below), no
federal funds had been used to support research on stem cells derived from either
human embryos or fetal tissue.6  The work at the University of Wisconsin and Johns
Hopkins University was supported by private funding from the Geron Corporation.
Private funding for experiments involving embryos was required because Congress
attached a rider to legislation that affected FY1996 National Institutes of Health
(NIH) funding.  The rider, an amendment originally introduced by Representative Jay
Dickey, prohibited HHS from using appropriated funds for the creation of human
embryos for research purposes or for research in which human embryos are
destroyed.  The Dickey amendment language has been added to each of the Labor,
HHS and Education appropriations acts for FY1997 through FY2004.7  For FY2004,
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7 (...continued)
of the Labor, HHS and Education appropriations acts in the following public laws:  FY1997,
P.L. 104-208; FY1998, P.L. 105-78; FY1999, P.L. 105-277; FY2000, P.L. 106-113;
FY2001, P.L. 106-554; FY2002, P.L. 107-116, and FY2003, P.L. 108-7.  
the provision is found in Section 510 of Division E, which is the Labor, HHS and
Education division of the FY2004 Consolidated Appropriations bill (P.L. 108-199).
It prohibits HHS from using FY2004 appropriated funds for
(1) the creation of a human embryo or embryos for research purposes; or 
(2) research in which a human embryo or embryos are destroyed, discarded, or
knowingly subjected to risk of injury or death greater than that allowed for
research on fetuses in utero under 45 CFR 46.208(a)(2) and Section 498(b) of the
Public Health Service Act (42 U.S.C. 289g(b)).  For purposes of this section, the
term “human embryo or embryos” includes any organism, not protected as a
human subject under 45 CFR 46 [the Human Subject Protection regulations] ...
that is derived by fertilization, parthenogenesis, cloning, or any other means from
one or more human gametes [sperm or egg] or human diploid cells [cells that
have two sets of chromosomes, such as somatic cells].
There is no similar federal prohibition on fetal tissue research; however, other
restrictions do apply.
Following the November 1998 announcement on the derivation of human
embryonic stem cells, NIH requested a legal opinion from HHS on whether federal
funds could be used to support research on human stem cells derived from embryos.
The January 15, 1999, response from HHS General Counsel Harriet Rabb found that
the Dickey amendment would not apply to research using human stem cells “because
such cells are not a human embryo within the statutory definition.”  The finding was
based, in part, on the determination by HHS that the statutory ban on human embryo
research defines an embryo as an organism that when implanted in the uterus is
capable of becoming a human being.  Human stem cells are not and cannot develop
into an organism; they lack the capacity to become organisms even if they are
transferred to a uterus.  As a result, HHS maintained that NIH could support research
that uses stem cells derived through private funds, but could not support research that
itself, with federal funds, derives stem cells from embryos because of the federal ban
in the Dickey amendment.
Shortly after the opinion by the HHS General Counsel was released, NIH
disclosed that the agency planned to fund research on stem cells derived from human
embryos once appropriate guidelines were developed and an oversight committee
established.  NIH Director Harold Varmus appointed a working group that began
drafting guidelines in April 1999.  Draft guidelines were published in the Federal
Register on December 2, 1999.  About 50,000 comments were received during the
public comment period, which ended February 22, 2000.  On August 25, 2000, NIH
published in the Federal Register final guidelines on the support of human
embryonic stem cell research.  The guidelines stated that studies utilizing “stem cells
derived from human embryos may be conducted using NIH funds only if the cells
were derived (without federal funds) from human embryos that were created for the
purposes of fertility treatment and were in excess of the clinical need of the
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8 According to media sources, as of Apr. 2001 only three grant applications had been
submitted to NIH, and one was subsequently withdrawn. (Washington FAX, Apr. 19, 2001.)
Presumably, scientists were reluctant to invest the time and effort into preparing the
necessary paperwork for the NIH grant application process when the prospects of receiving
federal funding were uncertain under the new Bush Administration.  (P. Recer, “Stem Cell
Studies said Hurt by Doubt.” AP Online, May 2, 2001.)  In a related development, one of
the leading U.S. researchers on stem cells, Roger Pederson of the University of California,
San Francisco, decided to move his laboratory to the United Kingdom for “the possibility
of carrying out my research with human embryonic stem cells with public support.”  (Aaron
Zitner, “Uncertainty Is Thwarting Stem Cell Researchers.”  Los Angeles Times, July 16,
2001, pp. A1, A8.)  Human embryonic stem cell research was approved overwhelmingly by
the House of Commons in Dec. 2000 and the House of Lords in Jan. 2001.
9 Rick Weiss, “Bush Administration Order Halts Stem Cell Meeting; NIH Planned Session
To Review Fund Requests.”  The Washington Post, Apr. 21, 2001, p. A2.
10 ibid.
individuals seeking such treatment.”  Under the guidelines, NIH would not fund
research directly involving the derivation of human stem cells from embryos; this
was prohibited by the Dickey amendment.
Other areas of research ineligible for NIH funding under the guidelines include
(1) research in which human stem cells are utilized to create or contribute to a human
embryo; (2) research in which human stem cells are combined with an animal
embryo; (3) research in which human stem cells are used for reproductive cloning of
a human; (4) research in which human stem cells are derived using somatic cell
nuclear transfer, i.e., the transfer of a human somatic cell nucleus into a human or
animal egg; (5) research utilizing human stem cells that were derived using somatic
cell nuclear transfer; and (6) research utilizing stem cells that were derived from
human embryos created for research purposes, rather than for infertility treatment.
NIH began accepting grant applications for research projects utilizing human
stem cells immediately following publication of the guidelines; the deadline for
submitting a grant application was March 15, 2001.  All such applications were to be
reviewed by the NIH Human Pluripotent Stem Cell Review Group (HPSCRG),
which was established to ensure compliance with the guidelines.  James Kushner,
director of the University of Utah General Clinical Research Center, served briefly
as chair of the HPSCRG. Applications would also have undergone the normal NIH
peer-review process.8  The first meeting of the HPSCRG was scheduled for April 25,
2001.  The HPSCRG  was to conduct an ethical review of human pluripotent stem
cell lines to determine whether the research groups involved had followed the NIH
guidelines in deriving the cell lines.  However, in mid April 2001, HHS postponed
the meeting until a review of the Clinton Administration’s policy decisions on stem
cell research was completed by the new Bush Administration.9  According to media
sources, the 12 HPSCRG members, whose names were not made public,  represented
a wide range of scientific, ethical and theological expertise and opinion, as well as
at least one “mainstream Catholic.”10
The Bush Administration conducted a legal review of the policy decisions made
during the Clinton Administration regarding federal support of stem cell research, as
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11 National Institutes of Health, Department of Health and Human Services.  Stem Cells:
Scientific Progress and Future Research Directions, June 2001.  The NIH scientific report
can be found at [http://stemcells.nih.gov/info/scireport/]
12 The Aug. 9, 2001, Remarks by the President on Stem Cell Research can be found at
[http://www.whitehouse.gov/news/releases/2001/08/20010809-2.html].
13 The White House, Fact Sheet on Embryonic Stem Cell Research, Aug. 9, 2001, found at
[http://www.whitehouse.gov/news/releases/2001/08/20010809-1.html].
well as a scientific review, prepared by NIH, of the status of the research and its
applications.  The scientific review was released on July 18, 2001, at a hearing on
stem cell research held by the Senate Appropriations Subcommittee on Labor, Health
and Human Services and Education.11  The NIH report did not make any
recommendations, but argued that both embryonic and adult stem cell research
should be pursued.
Bush Administration Stem Cell Policy.  On August 9, 2001, President
Bush announced that for the first time federal funds would be used to support
research on human embryonic stem cells, but funding would be limited to “existing
stem cell lines where the life and death decision has already been made.”12  President
Bush stated that the decision  “allows us to explore the promise and potential of stem
cell research without crossing a fundamental moral line, by providing taxpayer
funding that would sanction or encourage further destruction of human embryos that
have at least the potential for life.”  The President also stated that the federal
government would continue to support research involving stem cells from other
sources, such as umbilical cord blood, placentas, and adult and animal tissues,
“which do not involve the same moral dilemma.”
Under the Bush policy, federal funds may only be used for research on existing
stem cell lines that were derived (1) with the informed consent of the donors; (2)
from excess embryos created solely for reproductive purposes; and (3) without any
financial inducements to the donors.13  NIH was tasked with examining the derivation
of all existing stem cell lines and creating a registry of those lines that satisfy the
Bush Administration criteria.  According to the White House, this will ensure that
federal funds are used to support only stem cell research that is scientifically sound,
legal, and ethical.  Federal funds will not be used for (1) the derivation or use of stem
cell lines derived from newly destroyed embryos; (2) the creation of any human
embryos for research purposes; or (3) the cloning of human embryos for any purpose.
Agency Regulation.  Many entities and individuals that conduct research on
humans (“human subjects” research) are both federally and institutionally regulated.
Ex vivo embryos (those not in a uterus) are not considered “human subjects” for
these purposes, though federally funded research on them is regulated by the Dickey
Amendment as described above.  Stem cells and stem cell lines are not considered
“human subjects,” nor are they governed by the Dickey Amendment.
Two HHS agencies, FDA and NIH, regulate some aspects of stem cell research,
even if research on stem cell lines is not classified as “human subjects” research.
FDA, the agency that ensures the safety and efficacy of food, drugs, medical devices
and cosmetics, regulates stem cell research aimed at the development of any
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14 Xenotransplantation Action Plan:  FDA approach to the regulation of xenotransplantation.
Available at [http://www.fda.gov/cber/xap/xap.htm].
15 These documents are available at [http://www.fda.gov/cber/xap/xap.htm].
“product” subject to its approval.  NIH, the medical and behavioral research agency
within HHS, regulates stem cell research that it funds in compliance with President
Bush’s 2001 policy.  In accordance, NIH has created a Human Embryonic Stem Cell
Registry that lists the human embryonic stem cell lines that meet the eligibility
criteria as outlined in the Bush Administration stem cell policy.
FDA Regulation.  All of the human embryonic stem cell lines listed on the
NIH Human Embryonic Stem Cell Registry (see Table 2) have been grown on beds
of mouse “feeder” cells.  The mouse cells secrete a substance that prevents the human
embryonic stem cells from differentiating into more mature cell types (nerve or
muscle cells).  Infectious agents, such as viruses, within the mouse feeder cells could
transfer into the human cells.  If the human cells were transplanted into a patient,
these infected human cells may cause disease in the patient which could be
transmitted to close contacts of the patient and eventually to the general population.
Public health officials and regulatory agencies such as the FDA are specifically
concerned about retroviruses, which may remain hidden in the DNA only to cause
disease many years later, as well as any unrecognized agents which may be present
in the mouse cells.
The FDA defines xenotransplantation as “any procedure that involves the
transplantation, implantation, or infusion into a human recipient of either (a) live
cells, tissues, or organs from a nonhuman source, or (b) human body fluids, cells,
tissues or organs that have had ex vivo contact with live nonhuman animal cells,
tissues or organs.”14  So transplantation therapy involving Bush approved stem cell
lines, which all have been exposed to mouse feeder cells, would constitute
xenotransplantation.  Xenotransplantation products are subject to regulation by the
FDA under Section 351 of the Public Health Service Act (42 USC 262) and the
Federal Food, Drug and Cosmetic Act (21 USC 321 et.  seq.).  FDA has developed
guidance documents and the U.S. Public Health Service has developed guidelines on
infectious disease issues associated with xenotransplantation.15
During a Senate hearing on stem cell research held by the Health, Education,
Labor and Pensions Committee on September 5, 2001, HHS Secretary Thompson
stated that the FDA is overseeing 17 investigational protocols involving
xenotransplantation in other areas of clinical research that involve patients.
Therefore, the xenotransplantation-related public health concerns over the human
embryonic stem cell lines may not necessarily preclude the development of
treatments for patients.  While the problems presented by xenotransplantation for
clinical research are neither unique to stem cell research nor insurmountable, many
scientists believe it will be preferable to use sterile cell lines when attempting to treat
patients via stem cell transplantation, and scientists have been successful in
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16 National Institutes of Health, Department of Health and Human Services, Stem Cells:
Scientific Progress and Future Research Directions, June 2001, pp. 95-96.
17 See [http://stemcells.nih.gov/research/funding/].
18 Information about the NIH Human Embryonic Stem Cell Registry is available at
[http://stemcells.nih.gov/research/registry/index.asp].
developing human embryonic stem cells that can be maintained without the use of
mouse feeder cells.16
NIH Research Funding and Stem Cell Registry.  The Bush
Administration’s August 9, 2001, policy statement on stem cell research and the NIH
Stem Cell Registry effectively replaced the NIH stem cell guidelines that were
developed under the Clinton Administration and never fully implemented .  Grant
proposals for embryonic stem cell research undergo only the normal peer-review
process without the added review of the HPSCRG as had been specified under the
Clinton NIH stem cell guidelines.  In February 2002, NIH announced the approval
of the first expenditures for research on human embryonic stem cells.  Funding for
stem cell research by NIH is shown in Table 1.  The NIH website provides additional
information about current stem cell activities and funding opportunities.17
Table 1.  National Institutes of Health Funding
($ in millions)
FY2001 FY2002 FY2003
Stem cell research $306 $387 $521
Human embryonic stem cell (0) (10.7) (25)
Source:  NIH Budget Office, May 7, 2004.
The NIH Human Embryonic Stem Cell Registry lists stem cell lines that are
eligible for use in federally funded research and currently available to be shipped to
scientists.18  As shown in Table 2, the NIH registry originally listed  universities and
companies that had derived a total of 78 human embryonic stem cell lines which
were eligible for use in federally funded research under the August 2001 Bush
Administration policy.  However, many of these stem cell lines were found to be
either unavailable or unsuitable for research.  As of August 11, 2004, the NIH
registry listed a total of 21 stem cell lines available from seven sources as shown
below.
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19 Farhad Manjoo, “Thou Shalt Not Make Scientific Progress,” Salon.com, Mar. 25, 2004,
[http://www.salon.com/tech/feature/2004/03/25/stem_cells/index_np.html].
Table 2.  NIH List of Human Embryonic Stem Cell Lines Eligible
 for Use in Federal Research
Namea Number of stem cell
lines
Eligible Available
BresaGen, Inc., Athens, GA 4 3
Cell & Gene Therapy Institute (Pochon CHA University),
Seoul, Korea
2
Cellaritis AB, Goteborg, Sweden 3 2
CyThera, Inc., San Diego, CA 9 0
ES Cell International, Melbourne, Australia 6 6
Geron Corporation, Menlo Park, CA 7
Goteborg University, Goteborg,, Sweden 16
Karolinska Institute, Stockholm, Sweden 6 0
Maria Biotech Co. Ltd. — Maria Infertility Hospital Medical
Institute, Seoul, Korea
3
MizMedi Hospital — Seoul National University, Seoul,
Korea
1 1
National Center for Biological Sciences/Tata Institute of
Fundamental Research, Bangalore, India
3
Reliance Life Sciences, Mumbai, India 7
Technion University, Haifa, Israel 4 2
University of California, San Francisco, CA 2 2
Wisconsin Alumni Research Foundation, Madison, WI 5 5
Total 78 21
a. Entities in gray do not have stem cell lines available for shipment to U.S. researchers because of a
variety of scientific, regulatory and legal reasons.  The zeros entered in the “Available” column
indicate that “the cells failed to expand into undifferentiated cell cultures.”
Access to Stem Cell Lines. Many scientists, disease advocates and others
remain concerned that federally supported research on human embryonic stem cells
is limited to the number of cell lines that meet the criteria of the August 9, 2001 Bush
policy.  As stated above, currently 21 cell lines are available for research with federal
dollars, and an unpublished NIH report indicates that under a best case scenario, a
total of 23 human embryonic stem cell lines will ever be ready for use in research.19
Because the pre-August 9 cell lines were developed in the early days of human stem
cell research using older 1990s techniques, the cell lines not only have the problems
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20 Gareth Cook, “Clinic in U.S. Isolates 50 Lines of Stem Cells,” Boston Globe, June 9,
2004, p. A1.
21 The six diseases are beta thalassemia, neurofibromatosis type 1, Marfan’s syndrome,
myotonic dystrophy, fragile X syndrome, and Fanconi’s anemia.
22 Rick Weiss and Justin Gillis, “New Embryonic Stem Cells Made Available,” The
Washington Post, Mar. 4, 2004, p. A2.
23 For further information, see the Stanford University Medical Center website at
 [http://mednews.stanford.edu/stemcellQA.html].
of xenotransplantion described above, but they are harder to work with, not well
characterized, and somewhat unstable.
In reaction to the limitations imposed by the Bush policy, some U.S. research
groups have decided to develop additional human embryonic stem cell lines using
private funding.  In June 2004, a team of scientists at the Reproductive Genetics
Institute, a private fertility clinic in Chicago, announced that they had isolated 50 new
human embryonic stem cell lines from frozen embryos that were donated by patients
following fertility treatment.20  By using genetic diagnosis techniques, the Chicago
team was able to create stem cell lines that carry the gene for muscular dystrophy as
well as stem cell lines with the gene for six other diseases.21  The new stem cell lines
are to be used to understand the origins of disease-related symptoms and to develop
and test new treatments.
In March 2004, a Harvard University laboratory headed by Douglas Melton
announced that using private research dollars they had isolated 17 new human
embryonic stem cell lines.22  In order to perform this work it was necessary to build
a new laboratory so that the group’s federally funded research would be conducted
separately from research on the new stem cell lines.  Likewise, although the 17 stem
cell lines are available for use by other laboratories, any research using the new stem
cell lines must be performed at a facility that does not receive federal support.  The
Harvard group intends to raise $100 million in private funding to establish a stem cell
center in order to continue the work begun by Melton and his group of scientists.
In December 2002, Stanford University announced that a gift of $12 million
from an anonymous donor would be used to establish an institute that will use
expertise in stem cell biology and cancer biology to develop novel treatments for
cancer and other diseases.23  The new institute is headed by Dr. Irving Weissman, a
Professor in Cancer Biology at Stanford.  Scientists at the Institute for Cancer/Stem
Cell Biology and Medicine are developing new stem cell lines, some through the
process of SCNT, to study the disease process of a wide range of disorders including
cancer, diabetes, cardiovascular disease, autoimmune disease, allergies, and
neurological disorders such as Parkinson’s and Lou Gehrig’s disease.  Initial studies
are performed in mice; however, the work may be extended to human cells and eggs.
The new stem cell lines may allow investigators to better understand the biological
and genetic basis of a disorder and thereby develop new treatments.
In August 2002, the University of California at San Francisco established the
UCSF Developmental and Stem Cell Biology Program with a $5 million matching
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grant from Andy Grove, the chairman of Intel Corporation.  The program funds basic
studies (using both animal and human cells) in stem cell biology and their translation
into clinical practice with a goal of developing treatments for such diseases as
diabetes, cardiovascular disease, Parkinson’s disease, Alzheimer’s disease and spinal
cord injury.  UCSF and the University of Wisconsin are the only two universities in
the United States that have derived human embryonic stem cell lines that qualified
for inclusion on the NIH Stem Cell Registry.  This past winter, the new UCSF stem
cell program announced it had met the Grove “Stem Cell Challenge” and had raised
the total funding for the program to more than $11 million in gifts and matching
funds.  The program recently awarded $50,000 grants to four scientists who are
studying various aspects of stem cell biology.24
A worldwide survey of laboratories conducted by the Boston Globe found that
as of May 23, 2004, 128 human embryonic stem cell lines had been created since
August 9, 2001; all would be ineligible for use in federally funded research under the
Bush policy on stem cell research.25  More lines are being created in laboratories
overseas than in the United States, according to the survey.  The survey found that
94 were created in labs outside the United States and 34 were created in this country.
Of the 128 lines, 51 of the new stem cell lines are currently available for use, the
remaining cell lines are not  available for a variety of technical or legal reasons.  For
example, some cell lines have not yet been fully characterized to determine their
stability or suitability for research.  However, eventually their status is to be
determined by using laboratory techniques.  In Japan, stem cell lines are not allowed
to be shipped to laboratories in other countries.  In the United Kingdom, stem cell
lines cannot be shipped abroad until they have been processed by the new UK Stem
Cell Bank.26
In response to concerns over access to human embryonic stem cell lines, in April
2004, a group of over 200 Members of the House of Representatives sent a letter to
President Bush requesting that the Administration revise the current stem cell policy
and utilize the embryos that are created in excess of need during the treatment of
infertile couples.27  The letter points out that an estimated 400,000 frozen IVF
embryos28 “will likely be destroyed if not donated, with informed consent of the
couple, for research.”  According to the letter, “scientists are reporting that it is
increasingly difficult to attract new scientists to this area of research because of
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concerns that funding restrictions will keep this research from being successful. ...
We have already seen researchers move to countries like the United Kingdom, which
have more supportive policies.  In addition, leadership in this area of research has
shifted to the United Kingdom, which sees this scientific area as the cornerstone of
its biotech industry.”
Under the direction of the White House, NIH Director Elias A. Zerhouni sent
a letter in response to the House Members which restates the Bush Administration
position against using federal funds for research involving the destruction of human
embryos.29  The letter from NIH Director Zerhouni did contain the following sentence
which some observers believe indicates a potential future policy shift:  “And
although it is fair to say that from a purely scientific perspective more cell lines may
well speed some areas of human embryonic stem cell research, the president’s
position is still predicated on his belief that taxpayer funds should not ‘sanction or
encourage further destruction of human embryos that have at least the potential for
life.”30  Although White House spokesperson Claire Buchan stated that the sentence
does not indicate the president’s position has changed, supporters of stem cell
research point out that it concedes that science could benefit from additional stem
cell lines and that the president’s position now rests solely on ethical arguments.
A letter signed by 58 Senators urging President Bush to expand the current
federal policy concerning embryonic stem cell research was sent on June 4, 2004.31
The letter states that “despite the fact that U.S. scientists were the first to derive
human embryonic stem cells, leadership in this area of research is shifting to other
countries such as the United Kingdom, Singapore, South Korea and Australia.”
On July 14, 2004, HHS Secretary Thompson announced in a letter to Speaker
of the House Dennis Hastert that NIH would establish  Centers of Excellence in
Translational Stem Cell Research.32  The new centers will be funded by $18 millions
in grants over a four year period and will investigate how stem cells can be used to
treat a variety of diseases.  NIH will also create a National Embryonic Stem Cell
Bank that will collect in one location many of the stem cell lines that are eligible for
federal research funding.  In the letter to Speaker Hastert, Secretary Thompson  stated
that “before anyone can successfully argue the stem cell policy should be broadened,
we must first exhaust the potential of the stem cell lines made available with the
policy.”33  In reaction to the announcement, the President of the Coalition for the
Advancement of Medical Research stated that “creating a bank to house stem cell
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supply of stem cell lines for research.”34  The co-sponsors of the Stem Cell Research
Enhancement Act (H.R. 4682), Representative Michael Castle and Representative
Diana DeGette are quoted as saying that the plan is “a positive step forward but stops
short of providing researchers the full support they need.”35
State Legislation on Embryonic Stem Cell Research
The Dickey Amendment restricts federal funding for embryo research; however,
states are the principal sources of direct regulation of non-federally funded embryo
research.  State laws vary widely in their application and content.  Nebraska, New
Jersey, California and New Hampshire have enacted legislation directly regarding
stem cell research.  Nebraska prohibits the use of state funds for embryonic stem cell
research (Nebraska Health Care Funding Act §71-7606(3)).  New Hampshire’s
Safety and Welfare statutes (Title VXII §168-B: 16 (I, II)) circumscribe the
boundaries of permissible embryo research.36  New Jersey and California encourage
embryonic stem cell research, and permit state funding for it.  Kansas restricts its
bioscience funding to exclude research that would be “contrary to federal laws that
are in effect on the date of enactment of [the] act.”37 New Hampshire, Massachusetts,
Pennsylvania, Louisiana and Minnesota are currently considering pro-stem cell
legislation.38
California’s law, enacted in September 2002, was the nation’s first to expressly
permit and encourage research involving the derivation of human embryonic stem
cells and cloned embryos (California Health and Safety Code § 123440, 24185,
12115-7, 125300-320).  The law does not authorize practices that were previously
proscribed, but instead provides assurances to researchers and sponsors hesitant to
invest in embryonic stem cell research since the 2001 Bush policy took effect.  The
law has reportedly enticed several prominent researchers to move there from other
states.  A pro-stem cell coalition in California has placed an  initiative on the
November 2004 ballot that would generate $3 billion in state-bond funding for
embryonic stem cell research over the next 10 years and the establishment of a
California Institute for Regenerative Medicine.39
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New Jersey’s law, enacted in January 2004, specifically permits embryonic stem
cell research, but bans human cloning for reproductive purposes (NJ Permanent
Statutes, Title 26:2Z-2).  Like the California law, New Jersey’s stem cell statute
provides assurances to researchers and sponsors and does not contradict the 2001
Bush policy.  In May 2004, Governor James McGreevey signed a bill to create the
first state-funded embryonic stem cell research center, a $25 million endeavor.40  The
legislature funded the measure on June 25, 2004, passing a state budget that allocates
$9.5 million to the newly chartered Stem Cell Institute of New Jersey.41  The state
money is supposed to attract private investment, which Dr. Ira Black, the Institute’s
founding Director, says has already happened.42
In an effort to discourage abortion, 15 states restrict research on fetuses and
embryos that have been aborted, which may preclude some forms of stem cell
research.  Among the states with such restrictions are California, which encourages
stem cell research in other law, Pennsylvania, which is considering pro-stem cell
research legislation, and Nebraska, which prohibits the use of state funds for stem
cell research.  The restrictions on aborted fetal and embryonic tissue research vary
in scope among the states.  Arizona, Indiana, North Dakota, Ohio, Oklahoma, and
South Dakota prohibit research on living and nonliving fetuses or embryos.
Arkansas, California, Florida, Montana, and Nebraska prohibit research on aborted
live fetuses.  Massachusetts and Pennsylvania prohibit research on embryos and live
fetuses.  Illinois prohibits research on aborted living and nonliving fetuses.  Missouri
prohibits research on live fetuses before abortion.  The remaining 35 states do not
prohibit research using aborted fetal tissue.
Thirteen states have restrictions on research using fetal or embryonic tissue
derived from processes other than abortion (such as in vitro fertilization (IVF) or
cloning), which may also preclude some forms of stem cell research.  Among them
are Louisiana, which is considering pro-stem cell legislation, and North Dakota,
South Dakota and Illinois, which also prohibit research on fetuses and embryos.
Illinois prohibits research on fetuses and embryos.  Louisiana prohibits research on
fetuses and embryos in utero and in vitro.  Maine, New Mexico, Rhode Island and
Utah prohibit research on fetuses or embryos born or extracted alive.  This restriction
does not apply to pre-implantation in vitro fertilized embryos.  South Dakota
prohibits research on embryos outside of a woman’s body or on cells or tissues
derived from an embryo outside a woman’s body.  Minnesota prohibits research on
fetuses and on some live embryos.  Michigan and North Dakota prohibit research on
live embryos and fetuses, or cloned embryos.  The law in Virginia may prohibit
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research on cloned embryos or fetuses.43  Arkansas and Iowa prohibit research on
cloned embryos.  Thirty-seven states have no such restrictions.
Congressional Actions
A number of hearings have been held by both House and Senate committees on
the topic of stem cell research.  With regard to legislation, Congress addressed the
issue of stem cell research in the Consolidated Appropriations Act of 2004 (P.L. 108-
199) by including the Dickey Amendment  which bans almost all publically funded
human embryo research.  The act also bars the Patent and Trademark Office from
spending money “to issue patents on claims directed to or encompassing a human
organism.”  This restriction could potentially deter human stem cell research because
researchers might not be able to claim ownership of their work.  
P.L. 108-199 provides support for research using stem cells found in umbilical
cord blood by making $10,000,000 available to establish a National Cord Blood Stem
Cell Bank.  Two other bills, H.R. 2852 (Christopher Smith) and S. 1717 (Hatch),
both titled the Cord Blood Stem Cell Act of 2003, would amend the Public Health
Service Act to establish a National Cord Blood Stem Cell Bank Network to prepare,
store, and distribute human umbilical cord blood stem cells for the treatment of
patients and to support peer-reviewed research using this type of stem cell.  H.R.
2852 was referred to the Committee on Energy and Commerce.  S. 1717 was referred
to the Committee on Health, Education, Labor and Pensions.
H.R. 3960 (Millender-McDonald), the Stem Cell Replenishment Act of 2004,
was introduced on March 11, 2004.  H.R. 3960 authorizes the use of federal funds
for research on human embryonic stem cells irrespective of the date on which the
derivation process for the stem cells was initiated or completed.  The bill directs the
Director of NIH to review the guidelines and notices published by NIH with respect
to human embryonic stem cell research and revise the guidelines and notices to
ensure the availability of not less than 60 stem cell lines that are able to be used for
scientific research.  H.R. 3960 was referred to the House Committee on Energy and
Commerce on March 30, 2004.
H.R. 4682 (Castle), the Stem Cell Research Enhancement Act,  was introduced
on June 24, 2004.  H.R. 4682 amends the Public Health Service Act and directs the
Secretary of HHS, in consultation with the Director of NIH, to fund research on
embryonic stem cell lines derived after the August 9, 2001 policy established by the
Bush Administration.  In accordance with the Dickey Amendment, no federal funds
shall be used to derive stem cells or destroy embryos.  Stem cell lines derived after
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enactment must meet ethical guidelines established by the NIH.  Only embryos that
were originally created for fertility treatment purposes and in excess of clinical need
are eligible for stem cell derivation.  Only embryos that the individuals seeking
fertility treatments have determined will not be implanted in a woman and will be
discarded are eligible for stem cell derivation.  Written consent is required for
embryo donation.  The Secretary in consultation with the Director of NIH shall
promulgate guidelines 60 days after enactment.  These guidelines shall ensure that
federally funded researchers adhere to ethical considerations.  No federal funds shall
be used to conduct research on unapproved stem cell lines.  The Secretary shall
annually report to Congress about stem cell research.  H.R. 4682 has been referred
to the House Committee on Energy and Commerce.
On February 27, 2003, the House passed H.R. 534 (Dave Weldon), the Human
Cloning Prohibition Act of 2003 by a vote of 241-155.  H.R. 534 amends Title 18 of
the United States Code and would ban the process of human cloning as well as the
importation of any product derived from an embryo created via cloning.  Under this
measure, cloning could not be used for reproductive purposes or for research on
therapeutic purposes, which would have implications for stem cell research.  H.R.
534 includes a criminal penalty of imprisonment of not more than 10 years and a civil
penalty of not less than $1 million.  H.R. 534 is essentially identical to the measure
which passed the House in the 107th Congress (H.R. 2505).
During floor debate on H.R. 534, an amendment, H.Amdt. 4 (Robert Scott), was
agreed to by voice vote.  H.Amdt. 4 requires that the General Accounting Office
(GAO), in consultation with the National Academy of Sciences, conduct a study on
the impact of the cloning ban on medical technology and assess the need (if any) for
modification of the cloning ban contained in the bill.  A report to Congress with
findings and recommendations would be required within two years of enactment.  An
amendment in the nature of a substitute, H.Amdt. 5 (Greenwood), failed by a vote of
174 to 231.  The amendment would have prohibited human SCNT technology when
used to initiate a pregnancy but allowed SCNT to be used in medical research.
H.Amdt 5 is similar to H.R. 801 (Greenwood) (see below).
H.R. 534 was introduced on February 5, 2003, and reported (19-12 vote) by the
House Judiciary Committee on February 12, 2003 (H.Rept. 108-18).  During mark-
up, four amendments were defeated by 12-19 or by voice vote.  The amendments
attempted to either limit the ban to three years, exempt the importation of medical
treatments, exempt the use of cloning in research, or in the creation of additional
stem cell lines.  A fifth amendment that would add the GAO study was withdrawn
when Chairman Sensenbrenner assured his support if it was added to the bill during
floor debate.
A companion bill, S. 245 (Brownback), was introduced on January 29, 2003. 
It is similar to H.R. 534, except that  (1) it does not contain the ban on importation
of products derived from therapeutic cloning; and (2) it amends Title 4 of the Public
Health Service Act (42 U.S.C. 289 et seq.) instead of Title 18 of the United States
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Code.44  S. 245 includes a criminal penalty of imprisonment of not more than 10
years and a civil penalty of not less than $1 million.  It requires the General
Accounting Office to conduct a study to assess the need (if any) for any changes of
the prohibition on cloning in light of new developments in medical technology,  the
need for SCNT to produce medical advances, current public attitudes and prevailing
ethical views on the use of SCNT and potential legal implications of research in
SCNT.  The study is to be completed within four years of enactment.  S. 245 has
been referred to the Senate Health, Education, Labor, and Pensions Committee.
H.R. 801 (Greenwood), the Cloning Prohibition Act of 2003, was introduced on
February 13, 2003.  H.R. 801 would prohibit human reproductive cloning while
allowing cloning for medical research purposes, including stem cell research.  The
bill includes a civil penalty of up to $10 million and a criminal penalty of up to 10
years in prison for those convicted of using SCNT for human reproductive purposes,
or for importing the products of human cloning if the products would be used to
initiate a pregnancy.  The bill amends the Food, Drug and Cosmetic Act (21 U.S.C.
301 et seq.) and requires that all researchers performing SCNT on human cells must
register their research activity with the HHS Secretary; such registration would most
likely be submitted to the FDA.
H.R. 801 stipulates that all research involving human SCNT be conducted in
accordance with Part 50 (Protection of Human Subjects) and Part 56 (Institutional
Review Boards) of Title 21 of the Code of Federal Regulations (CFR).  Under the
bill, individuals whose cells are used for such research (presumably the donor of the
unfertilized egg and the donor of the somatic cell) would be considered human
subjects for the purposes of Parts 50 and 56 of 21CFR.  In addition to the
requirements under Parts 50 and 56 of 21CFR, the human cell donors must sign an
informed consent statement declaring that (1) the cells are donated for research
purposes; (2) the donor understands that federal law regulates SCNT and use of
SCNT to initiate a pregnancy is a criminal act; and, (3) the individual does not intend
for the donated cells to be used to initiate a pregnancy.  A sunset provision states that
the prohibition would expire 10 years after enactment.
H.R. 801 requires the Secretary of HHS to request a study reviewing the current
state of knowledge on (1) the biological properties of stem cells obtained from
embryos, fetal tissue, and adult tissue; (2) any biological differences of such stem
cells and the consequences for research and medicine; and (3) the ability of stem cells
to generate different types of tissue and their potential clinical uses.  The study must
be conducted by the Institute of Medicine or another appropriate public or nonprofit
private entity.
S. 303 (Hatch), the Human Cloning Ban and Stem Cell Research Protection Act
of 2003, was introduced on February 5, 2003.  Although S. 303 and H.R. 801 amend
different titles of the United States Code (S. 303 amends Title 18 and H.R. 801
amends Title 21), both bills would have the same effect:  human reproductive cloning
would be banned, but cloning for medical research purposes would be allowed,
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including stem cell research.45  S. 303 includes a criminal penalty of imprisonment
of not more than 10 years and a civil penalty of not less than $1 million.
S. 303 requires the Comptroller General to prepare a report within one year of
enactment that describes the actions taken by the Attorney General to enforce the
prohibition on human reproductive cloning, the personnel and resources used to
enforce the prohibition, and a list of any violations of the prohibition.  The
Comptroller General must also prepare a report within one year of enactment on
similar state laws that prohibit human cloning and actions taken by the states’
attorney general to enforce the provisions of any similar state law along with a list
of violations.  A report on the coordination of enforcement actions among the federal,
state and local governments must also be prepared by the Comptroller General within
one year of enactment, as well as a report on laws adopted by foreign countries
related to human cloning.
S. 303 also would amend the Public Health Service Act by requiring that human
SCNT be conducted in accordance with the ethical requirements (such as informed
consent, examination by an Institutional Review Board, and protections for safety
and privacy) contained in subpart A of 45CFR4646, or Parts 50 and 56 of 21CFR.47
In contrast, H.R. 801 requires that all such research shall be conducted in accordance
with Part 50 and 56 of 21CFR and does not refer to subpart A of 45CFR46.48
S. 303 contains a prohibition on conducting SCNT on fertilized human eggs
(oocytes), and states that “unfertilized blastocysts” shall not be maintained after more
than 14 days from its first cell division, aside from storage at temperatures less that
zero degrees centigrade.  S. 303 stipulates that a human egg may not be used in
SCNT research unless the egg is donated voluntarily with the informed consent of the
woman donating the egg; H.R. 801 contains a similar egg donation and informed
consent provision.  S. 303 also specifies that human eggs or unfertilized blastocysts
may not be acquired, received or otherwise transferred for valuable consideration if
the transfer affects interstate commerce.  Under S. 303, SCNT may not be conducted
in a laboratory in which human eggs are subject to assisted reproductive technology
treatments or procedures, such as in vitro fertilization for the treatment of infertility.
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Violation of these provisions in S. 303 regarding ethical requirements would result
in a civil penalty of not more than $250,000.  S. 303 has been referred to the Senate
Judiciary Committee.
Supporters of a total ban on human cloning, such as that contained in H.R. 534,
argue that a partial ban on human cloning, like the one in H.R. 801 or S. 303, would
be impossible to enforce.  Critics of the total ban on human cloning argue that SCNT
creates a “clump of cells” rather than an embryo, and that the ban would curtail
medical research and prevent Americans from receiving life-saving treatments
created overseas.
The U.S. Supreme Court has recognized in past cases certain personal rights as
being fundamental and protected from government interference.49  Some legal
scholars believe a ban on human cloning may be struck down by the Supreme Court
because it would infringe upon the right to make reproductive decisions which is
“protected under the constitutional right to privacy and the constitutional right to
liberty.”50  Other scholars do not believe that noncoital, asexual reproduction, such
as cloning, would be considered a fundamental right by the Supreme Court.  A ban
on human cloning research may raise other constitutional issues:  scientists’ right to
personal liberty and free speech.  In the opinion of some legal scholars, any
government limits on the use of cloning in scientific inquiry or human reproduction
would have to be “narrowly tailored to further a compelling state interest.”51
However, no case involving these issues is scheduled to come before the Supreme
Court this term.
International Actions on Embryonic Stem Cell Research
The international community has taken a variety of action regarding stem cell
research.  Action by the United Nations, which was considering a restrictive human
cloning treaty, is currently on hold until 2005.  The European Union (EU) clarified
its stem cell rules in November 2003, smoothing the path for EU funding and support
for human embryonic stem cell research.52  Under the terms of its sixth research
framework program(FP6), the EU may fund embryonic stem cell research regardless
of the date that the stem cells were procured from embryos.  A cut-off date, which
would have created a restriction similar to the one in the 2001 Bush policy, was
under consideration, but was dropped.53  FP6 allows funding for research on tissue
derived from “spontaneous or therapeutic abortion,” but not for the creation of
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human embryos for the purpose of stem cell procurement.54  FP6 implies but does not
state that it will allow funding for research on embryos that remain after IVF, in that
it “no longer requir[es] parental consent where embryos have to be destroyed in order
to produce embryonic stem cell lines.”55  According to Members of the European
Parliament, FP6 funding decisions should depend “both upon the contents of the
scientific proposal and the legal framework of the Member States involved.”56
EU member states are considering a range of legislation on the subject.  In Italy,
a proposal would prohibit any experiments on human embryos, the production of
embryos for research purposes, and any destruction of human embryos.  By contrast,
a proposal before the Spanish Parliament would allow research using surplus frozen
embryos that can no longer be used for reproductive purposes, provided that the
consent of the donor is given.  Sweden’s parliamentary committee on genetic
integrity reviewed the country’s regulation of stem cell research and proposed that
no prohibition relating to the production of fertilized eggs for research be introduced.
Other countries’ activities designed to regulate and promote stem cell research
have come to the attention of Congress.57 For example, in March 2004, the Canadian
government enacted legislation allowing stem cell and other research to be conducted
on donated embryos created but no longer needed for reproductive purposes.58
Australia permits the use of spare IVF embryos for stem cell research,59 and its
government has reportedly allotted $57.9 million to its National Stem Cell Centre.60
Singapore, which allows scientists to clone human embryos and keep them alive for
up to 14 days to extract the stem cells, is reported to have “research-friendly policies
and generous government funding have already helped jump-start the tiny city-state’s
nascent stem cell sector. ... Singapore and the New York-based Juvenile Diabetes
Research Foundation International launched a $3 million funding program to support
stem cell research [in Singapore], ... [and in May 2004, Singapore unveiled] its
resort-like Biopolis, created to give biotech researchers and their families a place to
live and work.”61  The United Kingdom’s Human Fertilisation and Embryology
Authority can issue licences permitting research on embryos less than 14 days old as
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well as cloning for research purposes.62  The UK “founded a new £16.5 million (USD
$30 million) stem cell center in Cambridge this week with a commitment to
fundamental research on both human embryonic and adult stem cells as a precursor
to studying therapeutic applications.”63  South Korea, the home of the doctor who
announced in February 2004 that he had cloned human embryos and extracted stem
cells from them, subsequently enacted legislation to regulate and license reproductive
cloning.64
Ethical Issues
Stem cell research is controversial not because of its goals, but rather because
of the means of obtaining some of the cells.  Research involving most types of stem
cells, such as those derived from adult tissues and umbilical cord blood, is
uncontroversial, except when its effectiveness as an alternative to embryonic stem
cells is debated.  The crux of the debate centers around embryonic stem cells, which
enable research that may facilitate the development of medical treatments and cures,
but which require the destruction of an embryo to derive.  In addition, because
cloning is one method of producing embryos for research, the ethical issues
surrounding cloning are also relevant.
As previously mentioned, the Bush Administration, a group of Representatives,
a group of Senators, and a group of Nobel Laureates have each presented their
respective positions on embryonic stem cell research.  In addition, various other
organizations, individuals, and councils have issued opinions and reports on the
topic.  Some groups, such as the Christian Legal Society,65 Focus on the Family,66
and the Christian Coalition,67 support the 2001 Bush policy.  Others, such as the
National Academies,68 the Coalition for the Advancement of Medical Research
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(CAMR),69 former First Lady Nancy Reagan,70 and former Presidents Gerald Ford,
Jimmy Carter, Bill Clinton71 favor more embryonic stem cell research than the Bush
policy allows.  Still others, such as the National Right to Life Committee72 and the
United States Conference of Catholic Bishops,73 oppose all embryonic stem cell
research.
Two presidential bioethics advisory panels  have considered the issues involved
in embryonic stem cell research.  The President’s Council on Bioethics (President’s
Council)74 published one report directly on the topic, Monitoring Stem Cell
Research,75 in which it sought to characterize the issues.  While the Council made no
recommendations there, in two other reports it has recommended that “Congress
should ... [p]rohibit the use of human embryos in research beyond a designated stage
in their development (between 10 and 14 days after fertilization),”76 and unanimously
recommended “a ban on cloning-to-produce-children,” with a 10-member majority
also favoring “a four-year moratorium on cloning-for-biomedical-research,” and a
seven-member minority favoring “regulation of the use of cloned embryos for
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biomedical research.”77  A predecessor to the President’s Council, the National
Bioethics Advisory Committee (NBAC),78 recommended federal funding for stem
cell research using “embryos remaining after infertility treatments,” but not for the
“derivation or use of embryos ... made for research purposes.”79
Detailed review of the assorted reports and statements reveals that, while
positions on embryonic stem cell research may be broadly categorized as for or
against, there is an array of finer distinctions present.  These finer distinctions in turn
reveal the variation in ethical and moral as well as factual beliefs.  The following
discussion breaks down the arguments about embryonic stem cell research according
to these finer distinctions, demonstrating both the complexity of the issues and the
points of resonance among the groups.
Embryo Destruction and Relief of Human Suffering.  Most positions
on embryonic stem cell research rest at least in part on the relative moral weight
accorded to embryos and that accorded to the prospect of saving, prolonging, or
improving others’ lives.  For some, the inquiry begins and ends with this question.
For instance, one opponent of the research, the American Life League, posits that
“human life begins at conception / fertilization and that there is never an acceptable
reason for intentionally taking an innocent human life.”80  Similarly, the United States
Conference of Catholic Bishops states that the research is immoral because it “relies
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on the destruction of some defenseless human beings for the possible benefit to
others.”81
Some groups explore the moral standing of human embryos, and also consider
the “duty to relieve the pain and suffering of others.”82  Others take the position that
embryos do not have the same moral status as persons.  They acknowledge that
embryos are genetically human, but hold that they do not have the same moral
relevance because they lack specific capacities, including consciousness, reasoning
and sentience.83  They conclude that performing research to benefit persons justifies
the destruction of embryos.  Acceptance of the notion that the destruction of embryos
can be justified in some circumstances forms the basis of pro-stem cell research
opinions, and is usually modified with some combination of the distinctions and
limitations that follow.
Viability of Embryos.  Some proponents of embryonic stem cell research
draw distinctions based upon whether an embryo is viable.  The idea behind this
distinction is that it is morally preferable for embryos that will not grow or develop
beyond a certain stage and/or  those that would otherwise be discarded to be used for
the purpose of alleviating human suffering.  This distinction has led some, though not
all, pro-life advocates to support embryonic stem cell research that does not destroy
embryos that are viable, meaning pre-implantation embryos, those created via cloning
that are incapable of full development, or those without a woman willing to carry
them to term.
Most supporters of some type of embryonic stem cell research touch on the
question of viability.  The 2001 Bush policy requires, among other things, use of only
excess (non-viable) embryos for federally-funded research.  One report of the
President’s Council explores the moral significance of viability that is based upon
“human choices” rather than an embryo’s “own intrinsic nature,” but draws no
conclusions.84  A second report broaches the subject of viability, recommending that
Congress ban both the transfer of a human embryo to a woman’s uterus for any
purpose other than to produce a live-born child, and also research conducted on
embryos more than 10 to 14 days after fertilization.85  The NBAC report touches on
the moral status of embryos in utero and those in vitro,86 though NBAC does not
specify whether viability was a key rationale for its recommendations.  A group of
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Representatives, a group of Senators,87 and CAMR imply but do not state a
distinction based on viability by expressly calling for the use of “excess” embryos
developed for IVF, and making no mention of those in utero.88  By contrast, the
National Academies and the group of Nobel Laureates more broadly support research
on embryos, making no mention of viability.
Purpose of Embryo Creation.  A separate distinction that often leads to the
same conclusions as viability is the purpose for which embryos are created.  This
distinction draws an ethical line based upon the intent of the people creating
embryos.  In the view of some, it is permissible to create an embryo for reproductive
purposes (such as IVF), but impermissible to create one with the intention of
destroying it for research.
Most groups at least note the potential ethical significance of reproductive
versus research motives for creating embryos.  The 2001 Bush policy draws a motive
distinction by including a requirement that federally funded research be conducted
only on embryonic stem cell lines derived from embryos created solely for
reproductive purposes.  NBAC draws the same distinction by recommending that
federal funding be used for embryos remaining after infertility treatment but not for
research involving the derivation or use of stem cells from embryos made for
research purposes or from embryos made using cloning (SCNT).89  The President’s
Council recommends that Congress ban attempts at conception by any means other
than the union of egg and sperm (essentially banning cloning via SCNT), but does
not specify whether embryos might be created in vitro specifically for research
purposes.90  A group of Representatives, a group of Senators, and CAMR imply but
do not state that embryos should not be created for research purposes.  They overtly
call for the use of “excess” embryos developed for IVF, and make no mention of
embryos created expressly for research.91  By contrast, the National Academies
supports the creation of embryos for research purposes, including via cloning
(SCNT), to “ensure that stem cell-based therapies can be broadly applied for many
conditions and people [by] overcoming  the problem of tissue rejection.”92  Mrs.
Nancy Reagan, her supporters, and the group of Nobel Laureates also take this
position.
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New and Existing Cell Lines.  A further distinction has been drawn based
upon the timing of the creation of embryonic stem cell lines.  Here, the premise is
that it is unacceptable to induce the destruction of embryos for the creation of new
lines.  However, in cases in which embryos have already been destroyed and the lines
already exist, it is morally preferable to use those lines for research to improve the
human condition.  
This was one central distinction drawn in the 2001 Bush policy, which limited
the use of federal funding to research on lines derived  on or before the date of the
policy.  Supporters of the Bush policy on both sides of the issue favor this distinction
as a compromise.  It allows research on some embryonic stem cell lines.  It deters the
future destruction of embryos for research.  The President’s Council writes that the
Bush policy mixes “prudence” with “principle, in the hope that the two might
reinforce (rather than undermine) each other.”93  The Council notes that the policy is
supported by what it titles a moralist’s notion of when one may benefit from prior
bad acts (referring to embryo destruction): it prevents the government from
complying in the commission of or encouraging the act in the future, and it reaffirms
the principle that the act was wrong.94  The same report also contains analyses of the
Bush policy that characterize distinction between new and existing cell lines as
“arbitrary,” “unsustainable,” and “inconsistent.”95  The Council itself takes no
position in the report on this or any other issue.
Opponents of the Bush policy on both sides of the issue view the distinction
between new and existing stem cell lines with reproach.  One side, which includes
The National Right to Life Committee and the United States Conference of Catholic
Bishops, objects because the distinction validates destruction of embryos, and in fact
rewards those who did so first with a monopoly.  The other side, which includes the
National Academies, a group of Representatives, a group of Senators, Nancy Reagan
and her supporters, Gerald Ford, CAMR, and the group of Nobel Laureates, objects
because the distinction limits the number of embryonic stem cell lines available for
research, particularly since the number of authorized lines are dwindling and are
“contaminated with mouse feeder cells.”96  Likewise, though NBAC recognized the
distinction between destroying embryos and using ones previously destroyed (e.g.,
“derivation of [embryonic stem] cells involves destroying the embryos, whereas
abortion precedes the donation of fetal tissue and death precedes the donation of
whole organs for transplantation”97), it still recommended future development of
embryonic stem cell lines.
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Consent of Donors.  There is consensus throughout a wide array of
viewpoints about embryonic stem cell research that embryos should only be obtained
for research with the consent of their biological donors.  This consent requirement
necessitates that embryos be taken only with donors’ knowledge, understanding, and
uncoerced agreement.  The donor consent requirement is consistent with the rules
governing human beings’ participation in research, and with individuals’ general
legal authority to make decisions regarding embryos they procreate.  A drawback of
the requirement is that it may restrict the number of embryos available for research
purposes.
The 2001 Bush policy contains a donor consent requirement.  It limits approved
stem cell lines to those derived with the informed consent of the donors, and obtained
without any financial inducements to the donors. The NBAC and the President’s
Council also favor donor consent requirements. The National Academies notes the
importance of informed consent in its discussion of stem cell research oversight
requirements.98  A group of Representatives and a group of Senators mention and
imply their support for donor consent requirements.99
Effectiveness of Alternatives.  One factual distinction that has been used
to support competing ethical viewpoints is the efficacy of alternatives to embryonic
stem cell research.  The promise of stem cell therapies derived from adult tissue and
umbilical cord blood have buttressed opposition to embryonic stem cell research.
These opponents argue that therapies and cures can be developed without the morally
undesirable destruction of embryos.  However, not all scientists agree that adult stem
cells hold as much potential as embryonic stem cells.  Most supporters of embryonic
stem cell research believe that it is the quickest and, perhaps in some cases, the only
path that will yield  results.  Supporters also stress that embryonic and other stem cell
research should be conducted collaboratively, so that they can inform one another.
Findings regarding the effectiveness of alternatives to embryonic stem cell
research are mixed.  The President’s Council notes that there is a “debate about the
relative merits of embryonic stem cells and adult stem cells.”100  Focus on the Family
cites promising non-embryonic stem cell research:  “adult stem cells may be as
“flexible” as embryonic ones and equally capable of converting into various cell
types for healing the body.”101  By contrast, the National Academies finds that the
“best available scientific and medical evidence indicates that research on both
embryonic and adult human stem cells will be needed.”102  NBAC finds in its
deliberations that “the claim that there are alternatives to using stem cells derived
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from embryos is not, at the present time, supported scientifically.”103  CAMR
supports both embryonic and adult stem cell research, and adds that “many scientists
believe and studies show that embryonic stem cells will likely be more effective in
curing diseases because they can grow and differentiate into any of the body’s cells
and tissues and thus into different organs.”104  Mrs. Nancy Reagan and her supporters
favor expedient approaches including embryonic stem cell research.105
Use of Federal Funding.  Some division over the support for and opposition
to embryonic stem cell research focuses on the question of whether the use of federal
funding is appropriate.  Those who oppose federal funding argue that the government
should not be associated with embryo destruction.106  They point out that embryo
destruction violates the “deeply held moral beliefs of some citizens,” and suggest that
“funding alternative research is morally preferable.”107  Proponents of federal funding
argue that it is immoral to discourage life-saving research by withholding federal
funding.  They point out that consensus support is not required for many federal
spending policies, as it “does not violate democratic principles or infringe on the
rights of dissent of those in the minority.”108  They argue that the efforts of both
federally supported and privately supported researchers are necessary to keep the
United States at the forefront of what they believe is a very important, cutting edge
area of science.  Furthermore, supporters believe that the oversight that comes with
federal dollars will result in better and more ethically controlled research in the field.
Groups’ positions on federal funding tend to mirror their positions on stem cell
research generally.  The Bush policy authorizes federal funding for some embryonic
stem cell research.  The President’s Council does  not take a position on the issue, but
notes the pros and cons, and stresses that there is a “difference between prohibiting
embryo research and refraining from funding it.”109  Focus on the Family generally
supports the President Bush and his policy, but is “disappointed by his decision to
allow federal funding of research on the existing stem cell lines.”110  NBAC finds the
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arguments in favor of federal funding more persuasive than those against it.111  The
National Academies, a group of Representatives, a group of Senators, Mrs. Nancy
Reagan and her supporters, CAMR, and the Nobel Laureates favor federal funding
for embryonic stem cell research.112
